Precision-Based Genomics in Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is. Objective: To look at gene mutations in men with prostate cancer as well as the course of their disease to better understand how gene mutations relate to the way the cancer progresses and responds to treatment. Eligibility: Adult males 18 and older with prostate cancer who have at least one of the gene mutations researchers want to study and/or have been treated for their cancer and have had complete elimination of their cancer or stable disease for a long time. Design: Participants will be screened with a review of their medical records. Their gene test results will be reviewed, if available. They will be asked questions over the phone or in person. Participants do not need to visit the NIH for this study. But if they visit NIH for another study, their data and test results will be collected. They may give blood and urine samples. They may give leftover tumor samples. These samples will be used to study their genes. Participants who do not come to NIH on regular basis will be contacted every 6 months by phone or e-mail. They will be asked questions about their health. Data from their medical records will be collected. Participants will have testosterone and prostate-specific antigen (PSA) tests. Participants may be invited to NIH to give blood samples for research. Participants on this study will be followed for life.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza raka prostaty
- •Wiek 18 lat lub więcej
- •Posiadanie określonych mutacji genów (PIK3, AKT, PALB2, BRIP1, RAD50, RAD51, RAD54, RB1, SPOP lub innych) wykazanych w testach genetycznych
- •Lub pozytywna odpowiedź na leczenie (całkowite ustąpienie raka lub długotrwała stabilizacja choroby)
- •Zdolność do zrozumienia badania i podpisania zgody uczestnika
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 17, 2026
- Sex
- Male only
Locations (11)
University of California San Diego
La Jolla, United States
University of California San Francisco
San Francisco, United States
NorthShore University HealthSystem
Evanston, United States
National Institutes of Health Clinical Center
Bethesda, United States
Dana Farber Cancer Institute, Boston, MA
Boston, United States
University of Michigan
Ann Arbor, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Mount Sinai Hospital
New York, United States
Weill Cornell Medicine
New York, United States
Oregon Health Sciences University
Portland, United States
University of Washington
Seattle, United States
Trial contact
Katherine O Lee-Wisdom, R.N.
Fatima H Karzai, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.